更多药企加入战局,恒瑞要去证明自己还是最耀眼的那一个。文|《中国企业家》记者谭丽平编辑|张昊头图来源|视觉中国就在A股“药王”恒瑞医药(以下简称“恒瑞”)确定港股发行价之后,“贵不贵”成了创新药板块投资者最核心的议题。这甚至被认为是之后一段时间的“风向标”,随着创新药市场有回暖迹象,启动港股IPO重新成为众多创新药企业的核心战略目标。不得不说,重新回归公司的恒瑞医药创始人孙飘扬运气不错。先是...
Source Link更多药企加入战局,恒瑞要去证明自己还是最耀眼的那一个。文|《中国企业家》记者谭丽平编辑|张昊头图来源|视觉中国就在A股“药王”恒瑞医药(以下简称“恒瑞”)确定港股发行价之后,“贵不贵”成了创新药板块投资者最核心的议题。这甚至被认为是之后一段时间的“风向标”,随着创新药市场有回暖迹象,启动港股IPO重新成为众多创新药企业的核心战略目标。不得不说,重新回归公司的恒瑞医药创始人孙飘扬运气不错。先是...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.